



2024 IKCS: EUROPE

INTERNATIONAL KIDNEY CANCER SYMPOSIUM

IKCSEU24 ABSTRACTS

		Key: Selected for Oral Selected for Poster Ad		
Poster Nbr	Title	PRESENTING AUTHOR		placement
A1	CLEC18A hinders clear cell renal cell carcinoma progression	Gustav	Jonsson	poster
A2	MCAM is a marker of ccRCC tumor vasculature that allows for enrichment of targeted ultrasound enhancing microbubbles	Haifeng	Yang	poster
A3	Patient-Derived Kidney Cancer Organoids to Predict Patient Therapeutic Responses	Issac	Toleman	poster ad
B1	Effects of nivolumab plus cabozantinib versus sunitinib on health-related quality of life in patients with advanced renal cell carcinoma: A mediation analysis of CheckMate 9ER	Shengsheng	Yu	poster
B2	Patient-reported outcomes (PROs) in LITESPARK-005: Belzutifan versus everolimus in patients with previously treated advanced renal cell carcinoma (RCC)	Cristina	Suarez	poster
B3	Relevance of health-related quality of life (HRQoL) assessment in renal cell carcinoma (RCC) patients. A real-world (RW) assessment	Ignacio	Durán	poster
D1	Current state of practice with digital pathology, molecular diagnostic methods and biobanking for renal cancer	James	Blackmur	poster
D2	Introduction of adjuvant immunotherapy (AIO) into the renal surgery pathway – are eligible patients receiving treatment in time in the UK NHS setting?	Melissa-Rose	Bennett	poster
E3	Effectiveness and safety of cabozantinib treatment in patients with advanced renal cell carcinoma (RCC) in Spanish and Portuguese real-world practice: Study SOGUG-SPRWEC	Oscar	Reig Torras	poster
E4	Influence of immunotherapy combinations on outcomes in sarcomatoid metastatic renal cell carcinoma: results from the UK renal oncology collaborative (UK ROC) – multicentre real world data.	Ricky	Frazer	poster
E5	Lenvatinib activity in previously treated patients with metastatic renal cell carcinoma (mRCC).	Javier	Gavira	poster
E6	Outcomes of advanced renal cell carcinoma patients who discontinued exclusive first-line immunotherapy for reasons other than disease progression	Macarena	Rey-Cardenas	poster
E7	REAL WORLD EXPERIENCE OF ADJUVANT PEMBROLIZUMAB IN RENAL CANCER PATIENTS	Lijo	James	poster
E8	Real-world recurrence patterns in Danish renal cell carcinoma patients	Rolf	Billeskov	poster
E9	RENO STUDY: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in northern Spain	Ibon	Gurruchaga Sotés	poster
E10	SHOULD THERAPEUTIC DRUG MONITORING BE USED WHEN DRUG INTERACTIONS ARE DETECTED IN CANCER RENAL PATIENT?	Eduard	Fort Casamartina	poster
F1	Comparison of deferred versus upfront cytoreductive nephrectomy in advanced renal cell carcinoma (aRCC)	Viktor	Grünwald	poster
F2	Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial	Viktor	Grünwald	poster
F3	Evaluation of bone response in metastatic renal cell carcinoma treated in 1st line with immunotherapy-based therapy	Fabien	Moinard-Butot	poster ad
F4	Phase 3 LITESPARK-005: Belzutifan versus everolimus in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC)	Guillermo	de Velasco	poster
G1	SAMETA: An open-label, three-arm, multicentre, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC)	Guillermo	de Velasco	poster
G2	An ongoing clinical Ph1-2 trial of orellanine as organ-specific therapy for patients with metastatic renal cell carcinoma and dialysis treatment	Boerje	Haraldsson	poster
G3	Efficacy by baseline characteristics in the phase 3 LITESPARK-005 study of belzutifan versus everolimus for previously treated advanced clear-cell renal-cell carcinoma (ccRCC)	Laurence	Albiges	oral
G4	Exploring and identifying differences in characteristics and outcomes between patients receiving cabozantinib plus nivolumab (CaboNivo) and sunitinib in CheckMate 9ER (CM9ER): a latent class analysis	David	Cella	oral
G5	Extended follow-up of KEYNOTE-B61: First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinoma (nccRCC)	Martin	Voss	oral

Poster Nbr	Title	PRESENTING AUTHOR		placement
G6	Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: a DaRenCa and NoRenCa Trial Evaluating the Impact of Surgery or No Surgery. The NORDIC-SUN-Trial	Niels	Fristrup	poster
G7	Posterior reversible encephalopathy syndrome in kidney cancer patients on immunotherapy -tyrosine kinase inhibitor combination	Ramachandran	Venkitaraman	poster
H1	A translational research approach to development of optimal renal cancer treatments in surgical and systemic therapy patients: The ARTIST study	Farhana	Easita	poster
H3	Circulating immune cells as determinants of outcomes in metastatic renal cell carcinoma treated with immune checkpoint inhibitors combinations	Ronan	Flippot	poster
H4	Multi-omics and spatial architecture of antigenic macrophage-CD8+ T cell crosstalk at the core of immune checkpoint blockade (ICB) response in advanced clear-cell renal cell carcinoma (aRCC)	Lisa	Kinget	poster ad
H5	PSMA-PET/CT as a response assessment tool in systemic therapy for metastatic renal cell carcinoma: initial clinical experience	Charis	Kalogirou	poster
I1	Associations between immune-related adverse events and clinical outcomes in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: a retrospective tertiary centre study	James	Jones	poster
J1	An Integrated Clinicopathological-Molecular Classifier Optimizes Risk Stratification of Localised Clear Cell Renal Cell Carcinoma (ccRCC)	Zayd	Tippu	oral
J2	Elevated soluble CD163 at baseline and increased PD1 expression on CD8pos T lymphocytes are associated with poor outcome in metastatic renal cell carcinoma.	Mie	Wolff Kristensen	poster ad
K1	Patterns of early 18F-FDG PET response to nivolumab (NIVO), and ipilimumab-nivolumab (IPINIVO) in patients with metastatic renal cancer (MRC)	Natalie	Charnley	poster
K2	Real-world characterization of patients treated with first-line checkpoint inhibitor-based combination therapy for advanced renal cell carcinoma: CARINA study post-hoc analysis	Natalie	Charnley	poster ad